AU2003213242A1 - Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents - Google Patents

Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents Download PDF

Info

Publication number
AU2003213242A1
AU2003213242A1 AU2003213242A AU2003213242A AU2003213242A1 AU 2003213242 A1 AU2003213242 A1 AU 2003213242A1 AU 2003213242 A AU2003213242 A AU 2003213242A AU 2003213242 A AU2003213242 A AU 2003213242A AU 2003213242 A1 AU2003213242 A1 AU 2003213242A1
Authority
AU
Australia
Prior art keywords
migraine
topiramate
group
formula
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003213242A
Other languages
English (en)
Inventor
Ian R Livingstone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of AU2003213242A1 publication Critical patent/AU2003213242A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003213242A 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents Abandoned AU2003213242A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35989402P 2002-02-26 2002-02-26
US60/359,894 2002-02-26
PCT/US2003/005463 WO2003072138A1 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Publications (1)

Publication Number Publication Date
AU2003213242A1 true AU2003213242A1 (en) 2003-09-09

Family

ID=27663315

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003213242A Abandoned AU2003213242A1 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Country Status (18)

Country Link
US (2) US20030225002A1 (cg-RX-API-DMAC7.html)
EP (1) EP1478400A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005518439A (cg-RX-API-DMAC7.html)
KR (1) KR101008326B1 (cg-RX-API-DMAC7.html)
CN (1) CN100352506C (cg-RX-API-DMAC7.html)
AU (1) AU2003213242A1 (cg-RX-API-DMAC7.html)
BR (1) BR0307951A (cg-RX-API-DMAC7.html)
CA (1) CA2419989A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20040846A2 (cg-RX-API-DMAC7.html)
IL (2) IL163720A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04008259A (cg-RX-API-DMAC7.html)
NO (1) NO20043984L (cg-RX-API-DMAC7.html)
NZ (1) NZ534874A (cg-RX-API-DMAC7.html)
PL (1) PL372393A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004126093A (cg-RX-API-DMAC7.html)
UA (1) UA81110C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003072138A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407729B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
JP2007523176A (ja) * 2004-02-17 2007-08-16 セプラコア インコーポレーテッド シタロプラム、エスシタロプラム又はシタロプラム代謝物質を用いる片頭痛又は頭痛疾患の治療又は病気の予防法
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
WO2007120747A2 (en) * 2006-04-13 2007-10-25 Nupathe Inc. Transdermal methods and systems for the delivery of anti-migraine compounds
EP2023894A4 (en) * 2006-04-25 2010-10-20 Applied Pharma Res FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
BRPI0918623A2 (pt) * 2008-09-17 2015-12-01 Hannover Med Hochschule métodos e kits para tratar distúrbios de cefaleia em grupo
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
WO2018067330A1 (en) * 2016-10-06 2018-04-12 Baylor College Of Medicine Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm
DK3955933T3 (da) * 2019-04-15 2024-02-12 Vistagen Therapeutics Inc Behandling af migræne

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
DE69733081T2 (de) * 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
EP0957928A1 (fr) * 1997-03-03 1999-11-24 Laboratoires Remilea Compositions d'extraits de plantes, leur procede de preparation, et compositions pharmaceutiques les renfermant
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
US6068999A (en) * 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
CN1182845C (zh) * 1999-01-19 2005-01-05 奥索-麦克尼尔药品公司 用于治疗集束性头痛的抗惊厥剂衍生物
EP1210118B1 (en) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug

Also Published As

Publication number Publication date
CN100352506C (zh) 2007-12-05
EP1478400A1 (en) 2004-11-24
CN1646168A (zh) 2005-07-27
RU2004126093A (ru) 2005-04-10
IL163720A (en) 2012-06-28
JP2005518439A (ja) 2005-06-23
US20030225002A1 (en) 2003-12-04
IL163720A0 (en) 2005-12-18
NO20043984L (no) 2004-09-23
PL372393A1 (en) 2005-07-25
NZ534874A (en) 2007-03-30
MXPA04008259A (es) 2005-05-27
KR20040091074A (ko) 2004-10-27
ZA200407729B (en) 2006-06-28
BR0307951A (pt) 2004-12-21
WO2003072138A1 (en) 2003-09-04
UA81110C2 (en) 2007-12-10
HRP20040846A2 (en) 2005-06-30
KR101008326B1 (ko) 2011-01-13
US20070099849A1 (en) 2007-05-03
HK1080731A1 (en) 2006-05-04
CA2419989A1 (en) 2003-08-05

Similar Documents

Publication Publication Date Title
US20030225002A1 (en) Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
US6627653B2 (en) Anticonvulsant derivatives useful for the treatment of depression
US20250302734A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
AU782344B2 (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
Trivedi et al. Original Research A Randomized Controlled Trial of the Efficacy and Safety
AU2018341091A1 (en) Use of cannabidiol in combination with 5-HT2B receptor agonists or amphetamins in the treatment of epilepsy
US20030060423A1 (en) Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors
Goonawardena et al. Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat
EP1404342A1 (en) Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
US6486198B1 (en) Compounds and methods for the treatment of post traumatic stress disorder
Pabis et al. Pharmacotherapy of aggressive behavior
WO2000042995A2 (en) Use of anticonvulsant derivatives for treating transformed migraine
US20030092636A1 (en) Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
HK1080731B (en) Use of a combination of anticonvulsant derivatives and anti-migraine agents in manufacture of medicaments
Tomson et al. The impact of background antiepileptic drugs on the efficacy and safety of pregabalin in treating partial-onset seizures: a post hoc analysis of combined clinical trials
AU2002323467A1 (en) Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
AU2002307542A1 (en) Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application